Pay in 4 interest-free payments of $6.64 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
GLP-1 receptor agonists suppress appetite and delay gastric emptying, which can lead to reduced overall nutrient intake if dietary quality is poor
Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022: Epic Research: Many Patients Maintain Weight Loss a Year After Stopping Semaglutide and Liraglutide (2024):
Key takeaways Wegovy (semaglutide) is a GLP-1 drug that is FDA approved for weight loss, cardiovascular risk reduction, and liver disease treatment
This weeks flashback revisits a July 2024 conversation recorded shortly after OpenAI released GPT-4o, a major leap forward in generative AI at the time
US$ 20.19
US$ 29.11
US$ 20.87
